{"filing":{"accession_number":"0001193125-26-296990","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-07-07","report_date":null,"primary_document":"d102781d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526296990/d102781d6k.htm"},"events":[{"id":16352,"run_id":14605,"accession_number":"0001193125-26-296990","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive phase 3 clinical trial results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease, with the drug meeting its primary endpoint of participants alive and free of invasive ventilation at 52 weeks. Sanofi intends to submit regulatory data for a label extension in the US in H2 2026. This is a material clinical milestone and regulatory development for a rare disease therapeutic, but it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the product pipeline that would affect investor assessment of the company's development progress and commercial prospects.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-07-07","form":"6-K","submitted_at":null,"items":[{"id":14427,"accession_number":"0001193125-26-296990","item_number":"EX-99.1","item_title":"d102781dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive phase 3 clinical trial results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease, with the drug meeting its primary endpoint of participants alive and free of invasive ventilation at 52 weeks. Sanofi intends to submit regulatory data for a label extension in the US in H2 2026. This is a material clinical milestone and regulatory development for a rare disease therapeutic, but it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the product pipeline that would affect investor assessment of the company's development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:19:59.762300+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14427,"accession_number":"0001193125-26-296990","item_number":"EX-99.1","item_title":"d102781dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive phase 3 clinical trial results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease, with the drug meeting its primary endpoint of participants alive and free of invasive ventilation at 52 weeks. Sanofi intends to submit regulatory data for a label extension in the US in H2 2026. This is a material clinical milestone and regulatory development for a rare disease therapeutic, but it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the product pipeline that would affect investor assessment of the company's development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:19:59.762300+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-07-07"}]}